Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmaco-Dynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2016
Price : $35 *
At a glance
- Drugs SAR 125844 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms SARMETA
- Sponsors Sanofi
- 16 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2015 Interim results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015 (n = 32).
- 29 Sep 2015 Planned End Date changed from 1 Feb 2017 to 1 May 2017 as reported by ClinicalTrials.gov.